Arzu Velioğlu

491 total citations
42 papers, 188 citations indexed

About

Arzu Velioğlu is a scholar working on Nephrology, Transplantation and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arzu Velioğlu has authored 42 papers receiving a total of 188 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Nephrology, 10 papers in Transplantation and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arzu Velioğlu's work include Renal Transplantation Outcomes and Treatments (10 papers), Dialysis and Renal Disease Management (10 papers) and Renal Diseases and Glomerulopathies (5 papers). Arzu Velioğlu is often cited by papers focused on Renal Transplantation Outcomes and Treatments (10 papers), Dialysis and Renal Disease Management (10 papers) and Renal Diseases and Glomerulopathies (5 papers). Arzu Velioğlu collaborates with scholars based in Türkiye, United States and Belgium. Arzu Velioğlu's co-authors include Serhan Tuğlular, Hakkı Arikan, Ebru Aşıcıoğlu, Esra Aydın Sünbül, Mehmet Koç, Bilge Bılgıç, Barış Bakır, Bülent Saka, Artür Salmaslıoğlu and Çeti̇n Özener and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Radiology.

In The Last Decade

Arzu Velioğlu

33 papers receiving 185 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arzu Velioğlu Türkiye 7 46 43 33 31 29 42 188
Rouba Garro United States 9 58 1.3× 69 1.6× 10 0.3× 53 1.7× 14 0.5× 26 247
Graham Roberts United Kingdom 9 56 1.2× 11 0.3× 15 0.5× 49 1.6× 33 1.1× 30 300
J.C. Regueiro López Spain 10 157 3.4× 17 0.4× 35 1.1× 36 1.2× 15 0.5× 41 306
Brenden E. Hursh Canada 7 81 1.8× 72 1.7× 39 1.2× 18 0.6× 13 0.4× 17 264
Edit Szederkényi Hungary 11 131 2.8× 79 1.8× 5 0.2× 54 1.7× 53 1.8× 30 303
Lindsay Griffin United States 11 55 1.2× 56 1.3× 19 0.6× 37 1.2× 14 0.5× 30 316
Arvind Nagra United Kingdom 7 50 1.1× 34 0.8× 2 0.1× 26 0.8× 6 0.2× 14 273
Samuel Torres‐Landa United States 8 200 4.3× 11 0.3× 6 0.2× 35 1.1× 4 0.1× 17 293
Mohammad H. Alkandari Kuwait 8 41 0.9× 18 0.4× 29 0.9× 31 1.0× 32 1.1× 23 250
Jon A. Gregg United States 7 121 2.6× 39 0.9× 8 0.2× 217 7.0× 112 3.9× 8 488

Countries citing papers authored by Arzu Velioğlu

Since Specialization
Citations

This map shows the geographic impact of Arzu Velioğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arzu Velioğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arzu Velioğlu more than expected).

Fields of papers citing papers by Arzu Velioğlu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arzu Velioğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arzu Velioğlu. The network helps show where Arzu Velioğlu may publish in the future.

Co-authorship network of co-authors of Arzu Velioğlu

This figure shows the co-authorship network connecting the top 25 collaborators of Arzu Velioğlu. A scholar is included among the top collaborators of Arzu Velioğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arzu Velioğlu. Arzu Velioğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Velioğlu, Arzu, et al.. (2025). The effect of COVID‐19 pandemic on personal hygiene behavior and the frequency of peritonitis in peritoneal dialysis patients. Therapeutic Apheresis and Dialysis. 29(3). 491–499.
2.
Velioğlu, Arzu, et al.. (2025). Ferritin to Albumin Ratio Predicts Mortality in Peritoneal Dialysis Patients. Therapeutic Apheresis and Dialysis. 29(4). 676–681. 1 indexed citations
3.
Hilbrands, Luuk B., Gabriel C. Oniscu, Ilaria Gandolfini, et al.. (2024). Current practices in prevention, screening, and treatment of diabetes in kidney transplant recipients: European survey highlights from the ERA DESCARTES Working Group. Clinical Kidney Journal. 18(1). sfae367–sfae367.
4.
Velioğlu, Arzu, Yasemin Özlük, Ahmet Burak Dirim, et al.. (2024). Prognosis is still poor in patients with posttransplant C3 glomerulopathy despite eculizumab use. Clinical Kidney Journal. 17(7). sfae190–sfae190. 4 indexed citations
5.
Pérez‐Sáez, María José, Núria Montero, Dolores Redondo‐Pachón, et al.. (2023). Immunosuppression of HLA identical living-donor kidney transplant recipients: A systematic review. Transplantation Reviews. 37(4). 100787–100787. 1 indexed citations
6.
Tufan, Aslı, et al.. (2023). Frailty and Dependency in Kidney Transplant Candidates. SHILAP Revista de lepidopterología. 33(1). 83–90.
7.
Yavuz, Di̇lek Gogas, Kadriye Aydın, Arzu Velioğlu, et al.. (2022). Clinical predictors of incipient vertebral fractures and bone mineral density in kidney transplant patients. European Spine Journal. 31(9). 2423–2430. 2 indexed citations
8.
Ilgın, Can, et al.. (2022). Peritoneal calprotectin level in peritoneal dialysis patients. Seminars in Dialysis. 36(3). 201–207.
9.
Oto, Özgür Akın, Seda Şafak, Berna Yelken, et al.. (2022). Long-Term Outcomes of Living-Related Kidney Donation for Alport Syndrome Spectrum: A Propensity Score-Matched Analysis. American Journal of Nephrology. 53(8-9). 628–635. 5 indexed citations
10.
Öztürk, Savaş, Arzu Velioğlu, & Serhan Tuğlular. (2022). Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. SHILAP Revista de lepidopterología. 31(1). 7–16.
11.
Tigen, Elif Tükenmez, et al.. (2022). Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience. Experimental and Clinical Transplantation. 20(2). 143–149. 1 indexed citations
12.
Ataş, Halil, Arzu Velioğlu, Hakkı Arikan, et al.. (2021). The prevalence of metabolic syndrome is increased in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. International Urology and Nephrology. 53(7). 1427–1434. 2 indexed citations
13.
Aşıcıoğlu, Ebru, Arzu Velioğlu, Hakkı Arikan, et al.. (2021). Baseline carotid intima‐media thickness is associated with cardiovascular morbidity and mortality in peritoneal dialysis patients. Therapeutic Apheresis and Dialysis. 25(6). 962–969. 3 indexed citations
14.
Çimşit, Canan, et al.. (2021). Assessment of peritoneal thickness using CT in relation to dialysis adequacy in peritoneal dialysis patients. Therapeutic Apheresis and Dialysis. 25(6). 954–961. 1 indexed citations
15.
Arikan, Hakkı, Arzu Velioğlu, Fatma Alıbaz-Öner, et al.. (2021). FRAX scores are increased in patients with ANCA-associated vasculitis. International Urology and Nephrology. 53(11). 2333–2339. 5 indexed citations
16.
Aşıcıoğlu, Ebru, et al.. (2021). Prognostic nutritional index is a predictor of mortality in elderly patients with chronic kidney disease. International Urology and Nephrology. 54(5). 1155–1162. 29 indexed citations
17.
Aşıcıoğlu, Ebru, et al.. (2021). Long-Term Predictors of Mortality in Peritoneal Dialysis Patients. Marmara University Open Access System. 30(3). 224–229. 2 indexed citations
18.
Velioğlu, Arzu, Bige Özkan, Hakkı Arikan, et al.. (2021). Low bone density, vertebral fracture and FRAX score in kidney transplant recipients: A cross-sectional cohort study. PLoS ONE. 16(4). e0251035–e0251035. 8 indexed citations
19.
Aşıcıoğlu, Ebru, Arzu Velioğlu, & Çeti̇n Özener. (2020). Peritoneal dialysis in the days of COVID‐19. Therapeutic Apheresis and Dialysis. 25(5). 709–710. 2 indexed citations
20.
Velioğlu, Arzu, Ebru Aşıcıoğlu, Elif Arı, et al.. (2016). Prevention of peritonitis in newly-placed peritoneal dialysis catheters: efficacy of oral prophylaxis with cefuroxime axetil - a preliminary study.. PubMed. 68(1). 27–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rouba Garro Breakdown of academic impact, for papers by Graham Roberts Breakdown of academic impact, for papers by J.C. Regueiro López Breakdown of academic impact, for papers by Brenden E. Hursh Breakdown of academic impact, for papers by Edit Szederkényi Breakdown of academic impact, for papers by Lindsay Griffin Breakdown of academic impact, for papers by Arvind Nagra Breakdown of academic impact, for papers by Samuel Torres‐Landa Breakdown of academic impact, for papers by Mohammad H. Alkandari Breakdown of academic impact, for papers by Jon A. Gregg
Rankless by CCL
2026